CareLit · DOI-Nachweis · Klinische Neurophysiologie
4-Aminopyridine (4-AP) and Visual Evoked Potentials (VEP)
DOI 10.1055/s-0034-1371266
Bibliografische Angaben
Nachweis in CareLit
Autor:innenS Merkelbach, A Hensel, B Seeliger, K Roch
ZeitschriftKlinische Neurophysiologie
Ausgabe03/2014
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Rationale: 4-Aminopyridine (Fampyra®) has been approved for the symptomatic treatment of impaired gait in multiple sclerosis. It has been suggested that it acts by blocking voltage-gated potassium channels in demyelinated axons, thereby preserving the action potential and improving nerve conduction. Method: We investigated the effects of 4-AP on VEP in 9 patients with MS (2 men, 7 women, mean age 52 ± 10 years, dura…
Zitieren
Zitierempfehlung
S Merkelbach, A Hensel, B Seeliger, K Roch (2014) 4-Aminopyridine (4-AP) and Visual Evoked Potentials (VEP). Klinische Neurophysiologie (03). https://doi.org/10.1055/s-0034-1371266
Mit CareLit weiterarbeiten